NASDAQ:CMRX Chimerix (CMRX) Stock Price, News & Analysis $2.81 -0.10 (-3.44%) (As of 12/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Chimerix Stock (NASDAQ:CMRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Chimerix alerts:Sign Up Key Stats Today's Range$2.75▼$3.0250-Day Range$0.83▼$2.9852-Week Range$0.75▼$3.39Volume2.12 million shsAverage Volume1.26 million shsMarket Capitalization$252.72 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingBuy Company OverviewChimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Read More… Chimerix Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScoreCMRX MarketRank™: Chimerix scored higher than 88% of companies evaluated by MarketBeat, and ranked 146th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChimerix has only been the subject of 2 research reports in the past 90 days.Read more about Chimerix's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Chimerix are expected to decrease in the coming year, from ($0.99) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chimerix is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chimerix is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChimerix has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.81% of the float of Chimerix has been sold short.Short Interest Ratio / Days to CoverChimerix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chimerix has recently decreased by 8.81%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChimerix does not currently pay a dividend.Dividend GrowthChimerix does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-2.49 Percentage of Shares Shorted0.81% of the float of Chimerix has been sold short.Short Interest Ratio / Days to CoverChimerix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chimerix has recently decreased by 8.81%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment0.22 News SentimentChimerix has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Chimerix this week, compared to 2 articles on an average week.Search Interest21 people have searched for CMRX on MarketBeat in the last 30 days. This is an increase of 425% compared to the previous 30 days.MarketBeat Follows3 people have added Chimerix to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Chimerix insiders have not sold or bought any company stock.Percentage Held by Insiders13.10% of the stock of Chimerix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chimerix's insider trading history. Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address CMRX Stock News HeadlinesWedbush Has Pessimistic Outlook of Chimerix Q4 EarningsDecember 15 at 1:41 AM | americanbankingnews.comHC Wainwright Has Positive Estimate for Chimerix Q4 EarningsDecember 15 at 1:07 AM | americanbankingnews.comForbes rich list released… #1 to be assassinated?Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.December 18, 2024 | Porter & Company (Ad)Wedbush Comments on Chimerix's Q2 Earnings (NASDAQ:CMRX)December 14, 2024 | americanbankingnews.comEdward White’s Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA PlansDecember 11, 2024 | markets.businessinsider.comChimerix (NASDAQ:CMRX) Earns Outperform Rating from WedbushDecember 11, 2024 | americanbankingnews.comInvestors Look Ahead to Key Inflation Data as US Futures Tread Water in Tuesday's PremarketDecember 10, 2024 | msn.comSmall Cap Soars On FDA Submission PlansDecember 10, 2024 | theglobeandmail.comSee More Headlines CMRX Stock Analysis - Frequently Asked Questions How have CMRX shares performed this year? Chimerix's stock was trading at $0.9625 on January 1st, 2024. Since then, CMRX stock has increased by 191.9% and is now trading at $2.81. View the best growth stocks for 2024 here. How were Chimerix's earnings last quarter? Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings data on Tuesday, August, 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.23). The biopharmaceutical company had revenue of $0.13 million for the quarter, compared to analyst estimates of $1.26 million. Who are Chimerix's major shareholders? Top institutional shareholders of Chimerix include Geode Capital Management LLC (0.94%), Connor Clark & Lunn Investment Management Ltd. (0.38%), Assenagon Asset Management S.A. (0.36%) and Valeo Financial Advisors LLC (0.09%). Insiders that own company stock include Michael T Andriole, David Jakeman, Michelle Laspaluto, Fred A Middleton and Robert J Meyer. View institutional ownership trends. How do I buy shares of Chimerix? Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chimerix investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), Pfizer (PFE) and Broadcom (AVGO). Company Calendar Last Earnings8/13/2024Today12/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMRX CUSIPN/A CIK1117480 Webwww.chimerix.com Phone(919) 806-1074Fax919-806-1146Employees72Year Founded2000Price Target and Rating Average Stock Price Target$8.50 High Stock Price Target$11.00 Low Stock Price Target$6.00 Potential Upside/Downside+202.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,100,000.00 Net MarginsN/A Pretax Margin-52,574.85% Return on Equity-50.78% Return on Assets-44.94% Debt Debt-to-Equity RatioN/A Current Ratio6.33 Quick Ratio6.33 Sales & Book Value Annual Sales$159,000.00 Price / Sales1,589.43 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book1.29Miscellaneous Outstanding Shares89,936,000Free Float78,154,000Market Cap$252.72 million OptionableOptionable Beta1.02 Social Links Get This Free Report This page (NASDAQ:CMRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.